Bone and Joint Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bone and joint infection markets reached a value of US$ 73.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 122.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.7% during 2024-2034.
The bone and joint infection market has been comprehensively analyzed in IMARC's new report titled "Bone and Joint Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bone and joint infection, medically known as osteomyelitis and septic arthritis, is a serious medical condition characterized by the presence of bacteria or other pathogens within the bone or joint tissues. This disease can result from direct contamination through an open wound, surgery, or the spread of bacteria from other parts of the body through the bloodstream. The symptoms of the illness can vary, but commonly include localized pain, swelling, redness, and warmth at the affected site. Patients might also experience limited mobility and fever, especially in cases of more severe condition. The diagnosis of bone and joint infection involves a combination of clinical findings, imaging studies, such as X-rays, MRIs, or CT scans, and laboratory tests. Blood cultures are often conducted to identify the causative pathogen and determine the most effective antimicrobial treatment. In some cases, a tissue biopsy may be required to confirm the diagnosis and guide appropriate management.
The escalating prevalence of bacterial, fungal, or viral diseases, in which pathogens enter the bloodstream and spread to various parts of the body, including the musculoskeletal system, is primarily driving the bone and joint infection market. In addition to this, the rising usage of potent antibiotics, such as vancomycin, cefazolin, clindamycin, etc., to treat the ailment and inhibit further microbial transmission is creating a positive outlook for the market. Moreover, the increasing adoption of physical and rehabilitative therapies, since they aid in refining overall motor skills, reducing pain, and ensuring the proper alignment of bones and joints, is also bolstering the market growth. Apart from this, the inflating application of advanced surgical interventions that involve the removal of infected tissues and implants, followed by the administration of targeted antibiotics, is acting as another significant growth-inducing factor. Additionally, the escalating demand for minimally invasive techniques, like arthroscopic procedures, to facilitate precise management of the infection while minimizing patient discomfort is also augmenting the market growth. Furthermore, the emerging popularity of immunotherapy and biologic treatments, which aim at boosting the body's natural defenses against bacterial invaders, thereby promoting tissue regeneration, is expected to drive the bone and joint infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bone and joint infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bone and joint infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bone and joint infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bone and joint infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bone and joint infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bone and joint infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bone and joint infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bone and joint infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bone and joint infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bone and joint infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of bone and joint infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bone and joint infection by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bone and joint infection across the seven major markets?
What is the size of the bone and joint infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bone and joint infection?
What will be the growth rate of patients across the seven major markets?
Bone and Joint Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bone and joint infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bone and joint infection market?
What are the key regulatory events related to the bone and joint infection market?
What is the structure of clinical trial landscape by status related to the bone and joint infection market?
What is the structure of clinical trial landscape by phase related to the bone and joint infection market?
What is the structure of clinical trial landscape by route of administration related to the bone and joint infection market?
The bone and joint infection market has been comprehensively analyzed in IMARC's new report titled "Bone and Joint Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bone and joint infection, medically known as osteomyelitis and septic arthritis, is a serious medical condition characterized by the presence of bacteria or other pathogens within the bone or joint tissues. This disease can result from direct contamination through an open wound, surgery, or the spread of bacteria from other parts of the body through the bloodstream. The symptoms of the illness can vary, but commonly include localized pain, swelling, redness, and warmth at the affected site. Patients might also experience limited mobility and fever, especially in cases of more severe condition. The diagnosis of bone and joint infection involves a combination of clinical findings, imaging studies, such as X-rays, MRIs, or CT scans, and laboratory tests. Blood cultures are often conducted to identify the causative pathogen and determine the most effective antimicrobial treatment. In some cases, a tissue biopsy may be required to confirm the diagnosis and guide appropriate management.
The escalating prevalence of bacterial, fungal, or viral diseases, in which pathogens enter the bloodstream and spread to various parts of the body, including the musculoskeletal system, is primarily driving the bone and joint infection market. In addition to this, the rising usage of potent antibiotics, such as vancomycin, cefazolin, clindamycin, etc., to treat the ailment and inhibit further microbial transmission is creating a positive outlook for the market. Moreover, the increasing adoption of physical and rehabilitative therapies, since they aid in refining overall motor skills, reducing pain, and ensuring the proper alignment of bones and joints, is also bolstering the market growth. Apart from this, the inflating application of advanced surgical interventions that involve the removal of infected tissues and implants, followed by the administration of targeted antibiotics, is acting as another significant growth-inducing factor. Additionally, the escalating demand for minimally invasive techniques, like arthroscopic procedures, to facilitate precise management of the infection while minimizing patient discomfort is also augmenting the market growth. Furthermore, the emerging popularity of immunotherapy and biologic treatments, which aim at boosting the body's natural defenses against bacterial invaders, thereby promoting tissue regeneration, is expected to drive the bone and joint infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bone and joint infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bone and joint infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bone and joint infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bone and joint infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bone and joint infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bone and joint infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bone and joint infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bone and joint infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bone and joint infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bone and joint infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of bone and joint infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bone and joint infection by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bone and joint infection across the seven major markets?
What is the size of the bone and joint infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bone and joint infection?
What will be the growth rate of patients across the seven major markets?
Bone and Joint Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bone and joint infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bone and joint infection market?
What are the key regulatory events related to the bone and joint infection market?
What is the structure of clinical trial landscape by status related to the bone and joint infection market?
What is the structure of clinical trial landscape by phase related to the bone and joint infection market?
What is the structure of clinical trial landscape by route of administration related to the bone and joint infection market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BONE AND JOINT INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BONE AND JOINT INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BONE AND JOINT INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BONE AND JOINT INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BONE AND JOINT INFECTION - UNMET NEEDS
10 BONE AND JOINT INFECTION - KEY ENDPOINTS OF TREATMENT
11 BONE AND JOINT INFECTION - MARKETED PRODUCTS
11.1 List of Bone and Joint Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Keflex (Cephalexin) - Pragma Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cefazolin - Baxter Healthcare Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Cipro (Ciprofloxacin Hydrochloride) - Bayer HealthCare
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BONE AND JOINT INFECTION - PIPELINE DRUGS
12.1 List of Bone and Joint Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 Afabicin - Debiopharm International
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BONE AND JOINT INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BONE AND JOINT INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BONE AND JOINT INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bone and Joint Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bone and Joint Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bone and Joint Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bone and Joint Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bone and Joint Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bone and Joint Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bone and Joint Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bone and Joint Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bone and Joint Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bone and Joint Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bone and Joint Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bone and Joint Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bone and Joint Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bone and Joint Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bone and Joint Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bone and Joint Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bone and Joint Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bone and Joint Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bone and Joint Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bone and Joint Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bone and Joint Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bone and Joint Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bone and Joint Infection - Access and Reimbursement Overview
16 BONE AND JOINT INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BONE AND JOINT INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BONE AND JOINT INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BONE AND JOINT INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BONE AND JOINT INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BONE AND JOINT INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BONE AND JOINT INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BONE AND JOINT INFECTION - UNMET NEEDS
10 BONE AND JOINT INFECTION - KEY ENDPOINTS OF TREATMENT
11 BONE AND JOINT INFECTION - MARKETED PRODUCTS
11.1 List of Bone and Joint Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Keflex (Cephalexin) - Pragma Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cefazolin - Baxter Healthcare Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Cipro (Ciprofloxacin Hydrochloride) - Bayer HealthCare
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BONE AND JOINT INFECTION - PIPELINE DRUGS
12.1 List of Bone and Joint Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 Afabicin - Debiopharm International
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BONE AND JOINT INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BONE AND JOINT INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BONE AND JOINT INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bone and Joint Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bone and Joint Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bone and Joint Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bone and Joint Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bone and Joint Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bone and Joint Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bone and Joint Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bone and Joint Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bone and Joint Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bone and Joint Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bone and Joint Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bone and Joint Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bone and Joint Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bone and Joint Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bone and Joint Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bone and Joint Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bone and Joint Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bone and Joint Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bone and Joint Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bone and Joint Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bone and Joint Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bone and Joint Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bone and Joint Infection - Access and Reimbursement Overview
16 BONE AND JOINT INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BONE AND JOINT INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BONE AND JOINT INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
